Literature DB >> 2753062

Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.

T Ankermann1, U Osterkamp, S R Santos, W Kirch.   

Abstract

In sixteen patients with arterial hypertension and differing degrees of renal function the pharmacokinetics and haemodynamic effects of nitrendipine have been studied after treatment for 7 days. The AUC (0-24) and the elimination half-life of nitrendipine were significantly increased; the AUC (0-24) in patients with renal failure (median creatinine clearance 27.1 ml x min-1) was 196 ng x ml-1 x h compared to 97.8 ng x ml-1 x h in control subjects (median creatinine clearance 94.4 ml x min-1). The corresponding elimination half-lives were 13.5 h in renal failure and 4.4 h in the controls. The haemodynamic effects of nitrendipine were not enhanced in the patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753062     DOI: 10.1007/bf00558065

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Effect of age on liver function with particular reference to bromsulphalein excretion.

Authors:  E N Thompson; R Williams
Journal:  Gut       Date:  1965-06       Impact factor: 23.059

2.  Pharmacokinetics of oral propranolol in chronic renal disease.

Authors:  D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

3.  Effects of nitrendipine in patients with chronic renal failure.

Authors:  A Dal Canton; C Esposito; M Sabbatini; M Altomonte; G Romano; P Veniero; F Uccello; V E Andreucci
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

4.  Drug interactions with nitrendipine.

Authors:  W Kirch; H J Hutt; H Heidemann; K Rämsch; H D Janisch; E E Ohnhaus
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

5.  [Determination of systolic time intervals. A non-invasive method for evaluation of left ventricle function].

Authors:  H Kuhn; F Loogen
Journal:  Dtsch Med Wochenschr       Date:  1980-02-15       Impact factor: 0.628

6.  Some recent pharmacological findings with nitrendipine.

Authors:  A Scriabine; C L Anderson; R A Janis; K Kojima; H Rasmussen; S Lee; U Michal
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

7.  Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers.

Authors:  J Kann; G J Krol; K D Raemsch; D E Burkholder; M J Levitt
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

8.  Mode of antihypertensive action of nitrendipine.

Authors:  S Kazda; B Garthoff; G Luckhaus
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

9.  Nitrendipine kinetics in normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

10.  Clinical pharmacokinetics of nimodipine in normal and impaired renal function.

Authors:  W Kirch; K D Rämsch; U Dührsen; E E Ohnhaus
Journal:  Int J Clin Pharmacol Res       Date:  1984
View more
  11 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.

Authors:  N J MacDonald; A C Grant; R S Rodger; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

7.  Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.

Authors:  V Mast; C Fischer; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

8.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

9.  Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure.

Authors:  H Kierdorf; A Müller; P M Blanke; J Gellert; B Heintz; K D Rämsch; M Wargenau; J Kindler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.